Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507451 | 0.90 | HRH3 (0.47) | HRH3OPRK1ROCK1NEK2 | |
| SCHEMBL4500823 | 0.87 | HRH3 (0.47) | HRH3OPRK1ROCK1NEK2ACSL1 | |
| SCHEMBL4497211 | 0.82 | HRH3 (0.46) | HRH3OPRK1ROCK1ACSL1 | |
| SCHEMBL4488322 | 0.79 | HRH3 (0.50) | HRH3 | |
| SCHEMBL4487264 | 0.78 | HRH3 (0.45) | HRH3ROCK1NEK2 | |
| SCHEMBL4485816 | 0.78 | HRH3 (0.51) | HRH3MAOAMAOB | |
| SCHEMBL4499059 | 0.77 | HRH3 (0.49) | HRH3 | |
| SCHEMBL4499952 | 0.75 | CHRNB2 (0.48) | HRH3MAOB | |
| SCHEMBL4498291 | 0.74 | NPC1 (0.54) | HRH3MAOB | |
| SCHEMBL4502300 | 0.74 | HRH3 (0.52) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608617-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1755593-B1 | NAPHTHALENE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | MCARTHUR SILVIA G | 2007-11-15 | — | — | US | disclosed |
| US-7259158-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1755593-A1 | NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HOFFMAN-LA ROCHE INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005117865-A1 | NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885MEN1 2140/4885KMT2A 588/4885 |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885MEN1 2140/4885KMT2A 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.